Metlife (MET) AI Stock Analysis

• Market Cap: $53.57B
• Dividend Yield: 2.72%
• Average Volume (3M): 3.32M
• Price to Earnings (P/E): 13.7
• Beta (1Y): 0.93
• Revenue Growth: 6.17%
• EPS Growth: 59.22%
• Country: US
• Employees: 45,000
• Sector: Financial
• Sector Strength: 75
• Industry: Insurance - Life
• EPS (TTM): 2.02
• Shares Outstanding: 665,026,060
• 10 Day Avg. Volume: 2,736,295
• 30 Day Avg. Volume: 3,319,643
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.40
• Enterprise Value/Revenue: 1.03
• Enterprise Value/Gross Profit: 3.87
• Enterprise Value/Ebitda: 10.75
• 1Y Price Target: $94.38
• Price Target Upside: 15.45% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14

• Rating: 77 Outperform
• Price Target: $92.00 ▲(12.54% Upside)

MetLife's overall stock score reflects strong financial performance and strategic initiatives, supported by positive technical indicators. While valuation is reasonable, the stock's momentum and strategic corporate events enhance its attractiveness. The earnings call provides confidence in future growth, despite some challenges.

Positive Factors

Capital Management

Robust repurchases of $1.4 billion exceeded estimates, showing strong capital management.

Investment Management

Analyst remains constructive on shares and believes shares could soon begin to experience multiple expansion following more disclosures around MetLife Investment Management.

Sales Growth

Solid sales growth in Asia and Latin America, with Asia experiencing a robust 9% YoY growth.

Negative Factors

Earnings Performance

MetLife’s 2Q25 result came in well below analyst forecast of $2.45 and Street consensus of $2.16.

Sector Performance

Underperformance in Retirement and Income Solutions and Asia sectors negatively impacted overall performance.

Underwriting Results

The biggest headwind in 2Q25 results was less favorable underwriting results in Group Benefits.

Metlife Business Overview & Revenue Model

Company Description

MetLife, Inc. is a leading global provider of insurance, annuities, and employee benefit programs, headquartered in New York City. The company operates in various segments, including U.S. Insurance Solutions, International, and Employee Benefits, offering a wide range of products such as life insurance, disability income insurance, dental insurance, and retirement solutions. With a presence in over 40 countries, MetLife is committed to helping its customers achieve financial security and peace of mind.

How the Company Makes Money

MetLife generates revenue primarily through premiums collected from its insurance and annuity products. The company offers life insurance, health insurance, and retirement services, with premiums being a significant source of income. Additionally, MetLife earns investment income from the assets it holds, which include bonds, stocks, and real estate, as it invests the premiums received. Another revenue stream comes from fees for asset management services, particularly within its retirement and employee benefit segments. MetLife also engages in partnerships with employers to provide group insurance products, enhancing its distribution channels and customer reach. Key factors contributing to its earnings include its strong brand presence, diversified product offerings, and strategic acquisitions that expand its market footprint.

Metlife Financial Statement Overview

Summary

MetLife's financial statements collectively portray strong profitability, stable financial health, and excellent cash flow generation. The income statement highlights efficient revenue management and moderate growth, while the balance sheet indicates prudent leverage and strong returns on equity. The cash flow analysis underscores robust cash generation, supporting operational and strategic goals. Minor concerns include declining EBITDA margins and stockholders' equity.

Income Statement

Metlife's TTM (Trailing-Twelve-Months) financial performance shows strong gross profit and net income, with a gross profit margin of 100% due to revenue equaling gross profit. The net profit margin is a healthy 6.15%, indicating efficient management of expenses relative to revenue. Revenue growth from the previous year is 4.74%, showing positive momentum in revenue generation. The EBIT margin is 6.95%, but a declining trend in EBITDA margin from the previous annual report suggests potential cost pressures. Overall, the income statement reflects solid profitability and moderate growth.

Balance Sheet

The balance sheet demonstrates a robust equity position, with a debt-to-equity ratio of 0.55, indicating moderate leverage. Return on equity (ROE) is 16.39%, reflecting strong profitability relative to shareholder investments. The equity ratio stands at 4.00%, highlighting a substantial asset base supported by equity. However, the decrease in stockholders' equity over the past few years may signal potential challenges in maintaining equity levels. Overall, the balance sheet indicates financial stability with manageable leverage.

Cash Flow

Cash flow analysis reveals significant strengths, with a free cash flow growth rate of 13.25% from the previous year, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 3.79, suggesting robust cash flow efficiency. The free cash flow to net income ratio is 3.67, further emphasizing the company's ability to convert earnings into cash. These metrics reflect strong cash flow management and capacity to fund operations and growth initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	72.40B	69.90B	66.41B	67.82B	63.33B	67.89B
Gross Profit	19.33B	18.96B	15.99B	18.79B	16.80B	15.47B
EBITDA	6.96B	7.37B	3.92B	7.97B	10.13B	8.46B
Net Income	4.50B	4.43B	1.58B	5.28B	6.86B	5.41B
Balance Sheet
Total Assets	688.32B	677.46B	687.58B	663.07B	759.71B	795.15B
Cash, Cash Equivalents and Short-Term Investments	313.06B	100.57B	302.05B	301.91B	367.50B	378.51B
Total Debt	15.08B	18.71B	18.83B	17.98B	17.43B	18.15B
Total Liabilities	660.56B	649.75B	657.33B	632.95B	691.96B	720.33B
Stockholders Equity	27.49B	27.45B	30.02B	29.88B	67.48B	74.56B
Cash Flow
Free Cash Flow	17.05B	15.12B	14.26B	11.37B	12.83B	11.51B
Operating Cash Flow	17.05B	15.12B	14.26B	11.37B	12.83B	11.51B
Investing Cash Flow	-12.19B	-11.49B	-10.25B	-2.62B	-11.19B	-18.57B
Financing Cash Flow	-2.65B	-3.13B	-2.94B	-9.95B	-1.38B	10.73B

Metlife Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 81.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MET, the sentiment is Positive. The current price of 81.75 is above the 20-day moving average (MA) of 78.94, above the 50-day MA of 77.93, and above the 200-day MA of 79.18, indicating a bullish trend. The MACD of 1.20 indicates Negative momentum. The RSI at 63.74 is Neutral, neither overbought nor oversold. The STOCH value of 71.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MET.

Metlife Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GL	78 Outperform	$11.34B	11.18	20.02%	0.72%	4.02%	13.01%
MET	77 Outperform	$53.57B	13.65	15.61%	2.72%	6.17%	59.22%
AFL	71 Outperform	$56.49B	23.88	9.15%	2.06%	-17.57%	-53.18%
PRU	71 Outperform	$38.31B	23.77	5.57%	4.92%	-1.80%	-42.18%
UNM	69 Neutral	$11.93B	8.38	13.95%	2.36%	1.69%	22.65%
Sector *	68 Neutral	$18.05B	11.73	10.24%	3.73%	9.66%	1.70%
PUK	68 Neutral	$33.63B	10.15	20.05%	1.78%	42.48%	304.90%

Metlife Corporate Events

MetLife Announces Redemption of Preferred Stock Series G

On September 2, 2025, MetLife announced its decision to redeem all outstanding shares of its 3.850% fixed rate reset non-cumulative preferred stock, Series G, with a liquidation preference of $1,000 per share. The redemption will occur on September 15, 2025, and will not include accrued dividends, which will be paid separately. This strategic move may impact MetLife’s financial operations and stakeholder interests by altering its capital structure.

MetLife Declares Dividends on Preferred Stock

On August 15, 2025, MetLife, Inc. announced the declaration of dividends on several series of its preferred stock, payable on September 15, 2025, to shareholders of record as of August 29, 2025. This announcement reflects MetLife’s ongoing commitment to providing returns to its shareholders and may impact investor perceptions and market positioning within the financial services industry.

MetLife Reports Q2 2025 Results with Revenue Growth

On August 6, 2025, MetLife, Inc. released its second-quarter results for 2025, highlighting a net income of $698 million and adjusted earnings of $1.4 billion. Despite a decline in adjusted earnings due to less favorable underwriting and lower investment margins, the company saw revenue growth driven by higher sales in Asia, Latin America, and EMEA. MetLife continued to execute its New Frontier strategy, focusing on strategic transactions to accelerate growth in asset management and retirement platforms, while managing expenses and returning approximately $900 million to shareholders.

MetLife Appoints New Chief Accounting Officer

On July 30, 2025, MetLife announced the appointment of Adrienne O’Neill as Executive Vice President and Chief Accounting Officer, effective September 2, 2025. O’Neill, who previously held key financial roles at Manulife Financial Corporation, will lead MetLife’s corporate accounting and reporting activities, contributing to the execution of the company’s New Frontier strategy. Her appointment is expected to enhance MetLife’s financial planning and analysis capabilities, supporting the company’s long-term growth objectives.

MetLife Announces $10 Billion Reinsurance Deal with Chariot

On July 1, 2025, MetLife, Inc. announced a significant agreement with Chariot Reinsurance, Ltd. to reinsure approximately $10 billion of structured settlement annuity contracts and group annuity contracts related to pension risk transfers. This strategic move is part of MetLife’s New Frontier strategy to enhance its diversified retirement platform and asset management business. The transaction marks the launch of Chariot Re, co-sponsored by MetLife and General Atlantic, with backing from Chubb and other investors. Chariot Re aims to reshape the life and annuity reinsurance market with its unique platform and experienced leadership team, led by CEO Cynthia Smith. The partnership is expected to drive growth and deliver innovative reinsurance solutions globally, while MetLife maintains its commitment to policyholders.

MetLife Releases Preliminary Q2 2025 Investment Income Estimates

MetLife, Inc. disclosed preliminary estimates of its variable investment income for the quarter ended June 30, 2025, ranging between $175 million and $225 million pre-tax. These figures, which include income from private equity, real estate, and other funds, are unaudited and subject to change as the company has not completed its financial closing procedures. Stakeholders are advised to be cautious in relying on these preliminary results, as they are not indicative of future performance and may differ from the final audited figures.

MetLife Shareholders Elect Directors and Ratify Auditor

At MetLife, Inc.’s annual meeting of common shareholders on June 17, 2025, shareholders elected eleven directors for terms expiring at the 2026 meeting, ratified Deloitte & Touche LLP as the independent auditor for 2025, and approved executive compensation on an advisory basis. These decisions reflect shareholder support for the company’s leadership and financial oversight, potentially impacting its governance and operational strategies moving forward.

MetLife Enters Note Purchase Agreement for Senior Notes

On June 17, 2025, MetLife, Inc. entered into a Note Purchase Agreement for the private placement of ¥87,840,000,000 in yen-denominated senior notes with varying interest rates and maturities. The proceeds from the sale are intended for refinancing existing debt and general corporate purposes, reflecting MetLife’s strategic financial management and positioning within the industry.